Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Small interfering RNAs (siRNA)

Small interfering RNAs (siRNA)

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Revisiting long-standing biological questions through evolving technologies.

Bioscience trends·2026

Same author

RNA activation as a precision dosing modality: MTL-CEBPA for controlled enzyme elevation in MPS I-H.

Frontiers in medicine·2026

Same author

A Modular and Scalable FPGA Platform for Intelligent, High-Throughput Image-Activated Cell Sorting.

Cytometry. Part A : the journal of the International Society for Analytical Cytology·2026

Same author

Glutathione-activatable bola dendrimers mediate tumor-specific cytosolic siRNA delivery <i>via</i> dynamic thiol-disulfide exchange.

Biomaterials science·2026

Same author

Self-assembling dendrimer nanoparticles in cancer therapy.

Nanomedicine (London, England)·2026

Same author

C/EBPβ stabilizes oxidative stress in triple-negative breast cancer cells, driving taxane resistance and immune evasion.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same journal

Limited evidence for evolutionarily conserved targeting of long non-coding RNAs by microRNAs.

Silence·2013

Same journal

Analysis of hairpin RNA transgene-induced gene silencing in Fusarium oxysporum.

Silence·2013

Same journal

cWords - systematic microRNA regulatory motif discovery from mRNA expression data.

Silence·2013

Same journal

Generation of a luciferase-based reporter for CHH and CG DNA methylation in Arabidopsis thaliana.

Silence·2013

Same journal

Strand-specific libraries for high throughput RNA sequencing (RNA-Seq) prepared without poly(A) selection.

Silence·2013

Same journal

MicroRNAs from the same precursor have different targeting properties.

Silence·2012

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Aptamer-targeted cell-specific RNA interference.

Jiehua Zhou¹, John J Rossi

¹Division of Molecular and Cellular Biology, Beckman Research Institute of City of Hope, City of Hope, Duarte, CA 91010, USA. jrossi@coh.org.

|March 16, 2010

Summary

This summary is machine-generated.

Aptamers are emerging as effective delivery vehicles for small interfering (si)RNAs, enhancing RNA interference therapeutics. This approach promises targeted delivery, improving efficacy and reducing side effects for various diseases.

More Related Videos

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Experiment Videos

Last Updated: Jun 15, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Area of Science:

Biotechnology
Molecular Biology
Therapeutics Development

Background:

Small interfering (si)RNAs (siRNAs) offer potent therapeutic gene silencing.
Efficient and safe delivery of siRNAs to target cells remains a major challenge in RNAi therapeutics.
Cell-surface protein-targeting aptamers are investigated as novel delivery vehicles.

Purpose of the Study:

To review recent advancements in using cell-internalizing aptamers for siRNA delivery.
To highlight the potential of aptamer-siRNA conjugates for targeted RNA interference therapies.
To discuss the optimization of aptamer-targeted siRNAs for clinical translation.

Main Methods:

Review of literature on aptamer-mediated siRNA delivery systems.
Analysis of studies employing cell-internalizing aptamers for targeted delivery.
Exploration of strategies to enhance aptamer-siRNA therapeutic efficacy and specificity.

Main Results:

Aptamers enable cell-type-specific and systemic delivery of siRNAs.
Aptamer-based delivery can improve therapeutic efficacy of siRNAs.
This strategy helps reduce off-target effects associated with siRNA administration.

Conclusions:

Aptamer-guided siRNA delivery represents a promising strategy for targeted RNAi therapeutics.
Further optimization of aptamer-siRNA systems is crucial for successful clinical translation.
This approach holds potential for treating a variety of diseases with enhanced precision.